![Manni Mohyuddin: Vague enrollment criteria in smoldering myeloma trials opens door to harm/over-interventionalism](https://oncodaily.com/pub/uploads/2023/11/download-72-e1702237868297.jpg)
Photo taken from Manni Mohyuddin/X
Dec 11, 2023, 11:21
Manni Mohyuddin: Vague enrollment criteria in smoldering myeloma trials opens door to harm/over-interventionalism
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on X/Twitter:
“Vague enrollment criteria in smoldering myeloma trials opens door to harm/over-interventionalism. The median plasma cell percentage was only 20%, and the most common high-risk abnormality was gain1q.
Many of these patients would have stayed stable off therapy for years.”
Source: Manni Mohyuddin/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023